一个mTOR-Tfeb-Fabp7a轴通过减缓心脏衰老改善心肌病
Yonghe Ding1, Xueling Ma1,2, Feixiang Yan1
1Department of Biochemistry and Molecular Biology, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Aging cell
|September 9, 2025
概括
加快的心脏衰老是BAG3心肌病变的关键病理. 操纵mTOR-Tfeb-Fabp7a通路可以减轻这种情况,为扩张性心肌病提供治疗效益.
科学领域:
- 心血管生物学 心血管生物学
- 分子遗传学 分子遗传学
- 衰老研究研究 衰老研究
背景情况:
- BAG3基因突变导致扩张性心肌病,但潜在的病理事件需要识别用于治疗向.
- 哺乳动物对拉巴胺素 (mTOR) 抑制的标显示出心脏保护作用,转录因子EB (Tfeb) 作为下游信号标.
研究的目的:
- 用斑马鱼模型发现BAG3相关心肌病变的新病态事件.
- 研究操纵mTOR-Tfeb-Fabp7a轴在心脏功能障碍和衰老中的治疗潜力.
主要方法:
- 产生了一个心肌细胞特异的转基因斑马鱼系,过度表达Tfeb (Tg[cmlc2:tfeb]).
- 在斑马鱼和非洲绿松石鱼中进行遗传研究,包括转录组分析.
- 利用了脂肪酸结合蛋白7a (Fabp7a) 的药理抑制.
主要成果:
- 在BAG3心肌病模型中,Tfeb过度表达挽救了蛋白质稳定和心脏功能,缓解了心脏加速衰老.
- 在BAG3心肌病模型中观察到Fabp7a表达升高;其过度表达诱导心脏病理和衰老.
- 在老年鱼心脏中发现Fabp7a表达升高,其抑制减轻了心脏衰老.
结论:
- 加快的心脏衰老是BAG3心肌病变的关键病理事件.
- mTOR-Tfeb-Fabp7a信号轴代表了BAG3心肌病和心脏衰老的潜在治疗标.
相关概念视频
Cardiomyopathy III: Hypertrophic Cardiomyopathy
416
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
416
Cardiomyopathy II: Dilated Cardiomyopathy
480
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
480
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K


